A Fat in Olive Oil Linked to Slower Alzheimer’s Progression in New Study

A single fatty acid circulating in the blood may help determine how quickly memory problems turn into Alzheimer’s disease, according to new research published in Scientific Reports. A team of Spanish researchers led by Farida Dakterzada and Gerard Piñol-Ripoll of the Universitat de Lleida and the Hospital Universitari Santa Maria found that people with mild cognitive impairment who carried higher levels of oleic acid in their plasma were less likely to progress to full Alzheimer’s disease over nearly five years of follow-up. Strikingly, the association appeared in both men and women, although the precise statistical signature differed by sex, reinforcing a growing conviction in the field that lipid biology is not a background detail in neurodegeneration but a central player.

The study set out to answer a question that has long been underexplored: do men and women differ in the fatty acid profiles associated with Alzheimer’s disease, and if so, how do those differences map onto disease status and progression? Alzheimer’s is the most common cause of dementia worldwide, and women bear a disproportionate share of the burden, both in prevalence and, some studies suggest, in the pace of decline after diagnosis. Because lipids are intimately involved in the construction and maintenance of neuronal membranes, in inflammation, and in the clearance of amyloid-β, the sticky protein that accumulates in Alzheimer brains, sex-linked differences in fat metabolism could help explain why the disease unfolds differently in men and women.

To probe this, the researchers analyzed fatty acid profiles in two body fluids that offer complementary windows onto brain health. Cerebrospinal fluid, the clear liquid bathing the brain and spinal cord, was sampled in 198 participants; plasma, the cell-free fraction of blood, was sampled in 286 participants spanning the full Alzheimer’s continuum, from cognitively healthy controls to individuals with mild cognitive impairment, often considered a transitional stage, to those with diagnosed Alzheimer’s disease. The analytical technique, gas chromatography with flame ionization detection, allowed the team to quantify individual fatty acid species precisely, from saturated fats such as palmitic and stearic acid to monounsaturated fats such as oleic and palmitoleic acid and polyunsaturated fats of the omega-3 and omega-6 families.

The participants with mild cognitive impairment were then followed for an average of 58 months, with a standard deviation of 12.5 months, giving the team a longitudinal dimension that many cross-sectional biomarker studies lack. This meant the researchers could ask not merely whether fatty acid profiles differ between diagnostic groups at one moment in time, but whether a particular lipid signature at baseline predicted who would cross the clinical threshold into Alzheimer’s disease during the years that followed.

Perhaps the most headline-grabbing finding concerned oleic acid, the monounsaturated fatty acid designated C18:1n-9, which is abundant in olive oil and is also synthesized endogenously in the human body by the enzyme stearoyl-CoA desaturase. In men, higher plasma oleic acid was associated with lower odds of progressing from mild cognitive impairment to Alzheimer’s disease, with an odds ratio of 0.666 per unit increase. In women, higher plasma oleic acid was associated with a longer time to progression, captured by a hazard ratio of 0.404. In plain terms, men with more oleic acid in their blood were less likely to convert at all, while women with more oleic acid took longer to convert. The convergence of both signals in the same direction, protective, across both sexes, gives the finding a robustness that isolated statistical associations often lack.

Other lipid signals emerged, but only within one sex. In men, a higher anti-inflammatory index in cerebrospinal fluid, a composite measure reflecting the balance of fatty acids with anti-inflammatory potential, was associated with dramatically lower odds of having Alzheimer’s disease rather than mild cognitive impairment, with an odds ratio of 0.025. At the same time, higher cerebrospinal fluid levels of alpha-linolenic acid, an omega-3 fatty acid found in plant foods, were paradoxically associated with higher odds of Alzheimer’s disease in men, with an odds ratio of 2.826. In women, higher cerebrospinal fluid levels of palmitoleic acid, a monounsaturated fatty acid, were associated with lower odds of amyloid-β positivity, meaning these women were less likely to show the molecular hallmark of Alzheimer’s pathology. Taken together, these sex-stratified results suggest that the fatty acid landscape of Alzheimer’s disease is not uniform, and that pooling men and women indiscriminately may obscure biologically meaningful patterns.

What could explain a protective link between a monounsaturated fat and cognitive decline? Several mechanisms are plausible based on established fatty acid biology. Oleic acid is a major component of membrane phospholipids, where it influences membrane fluidity and the behavior of membrane-embedded proteins, including the enzymes involved in amyloid precursor protein processing. Monounsaturated fats are also relatively resistant to oxidative damage compared with highly polyunsaturated fats, which are prone to peroxidation, a chain reaction of lipid degradation that generates toxic byproducts and is a prominent feature of aging brains. In addition, oleic acid and its derivatives participate in signaling pathways that modulate inflammation, and chronic neuroinflammation is widely regarded as an accelerant of Alzheimer pathology. The anti-inflammatory index finding in men is consistent with this general framework, since it suggests that a lipid milieu tilted toward inflammation-resolving species tracks with a less advanced disease state.

The authors are careful, appropriately so, to flag the interpretive limits of their work. Reverse causation remains a possibility: it could be that the neurodegenerative process itself, or the metabolic changes that accompany it, alters fatty acid levels in plasma and cerebrospinal fluid, rather than fatty acids influencing the disease trajectory. A person in the early stages of Alzheimer’s may eat differently, metabolize fats differently, or experience liver and lipid-transport changes that reshape their circulating lipid profile. Residual confounding cannot be excluded either, since many unmeasured variables, from genetics beyond the apolipoprotein E status typically adjusted for to medications, physical activity, and overall diet quality, could correlate with both oleic acid levels and dementia risk. The finding that higher alpha-linolenic acid in cerebrospinal fluid was associated with higher odds of Alzheimer’s in men is itself a cautionary illustration that more of a supposedly healthy fat is not automatically protective, and that compartment-specific measurements in the brain’s own fluid can diverge from what is seen in blood.

These caveats notwithstanding, the study adds to a compelling body of evidence linking lipid metabolism to Alzheimer’s disease. The apolipoprotein E ε4 allele, the strongest genetic risk factor for late-onset Alzheimer’s, is a lipid-transport protein, a fact that has long hinted at the centrality of fat handling in the disease. Omega-3 fatty acids such as docosahexaenoic acid, abundant in fish, have been studied for decades as potential protectors of cognitive health, with mixed results in clinical trials. The present study shifts some attention toward the monounsaturated family and toward the value of stratifying analyses by sex, an approach increasingly demanded across biomedical research after years in which women were underrepresented or sex differences were simply averaged away.

For now, the findings should be read as an epidemiological clue rather than dietary prescription. The researchers did not set out to test whether olive oil supplementation prevents dementia, and no amount of oleic acid in a healthy diet has been shown, by this study alone, to slow cognitive decline in people already diagnosed with mild cognitive impairment. What the work does establish is a measurable association, robust enough to appear in both men and women with different statistical signatures, between higher circulating levels of one common dietary and endogenous fatty acid and a slower march from subtle memory impairment toward Alzheimer’s disease. Follow-up studies, ideally with longitudinal lipid measurements, dietary assessment, and mechanistic work in cell and animal models, will be needed to determine whether oleic acid is a genuine modifier of the disease process, a biomarker of some underlying protective state, or both. In a field where disease-modifying treatments remain hard-won and partially effective, even a modifiable correlate of slower progression is worth the scientific community’s full attention.

Subject of Research: Association between plasma oleic acid levels and progression from mild cognitive impairment to Alzheimer's disease, analyzed with sex-stratified fatty acid profiling of blood and cerebrospinal fluid.

Article Title: Higher plasma oleic acid is associated with slower progression from mild cognitive impairment to Alzheimer’s disease in men and women

Article References: Dakterzada, F., Jové, M., Cantero, J. L., Mota-Martorell, N., Pamplona, R., & Piñol-Ripoll, G. (2026). Higher plasma oleic acid is associated with slower progression from mild cognitive impairment to Alzheimer’s disease in men and women. Scientific Reports. https://doi.org/10.1038/s41598-026-74033-1

Image Credits: AI Generated

DOI: 10.1038/s41598-026-74033-1

Keywords: Alzheimer's disease, oleic acid, fatty acids, mild cognitive impairment, biomarkers, lipid metabolism, cerebrospinal fluid, sex differences, neurodegeneration, Scientific Reports, amyloid-beta, plasma